Armata Pharmaceuticals Inc 2025年度报告

(I.R.S. Employer Identification No.) (310) 665-2928(Registrant’s telephone number, including area code) (Address of principal executive offices, including zip code)Securities registered pursuant to Section12(b)of the Act: Securities registered pursuant to Section 12(g) of the Act: None. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule405 of the Securities Act.Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section13 or Section15(d)of the Exchange Act.Yes☐No☒ Indicate by check mark whether the Registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12months (or for such shorter period that the Registrant was required to file such reports), and (2)has been subject to such filingrequirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or anemerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” inRule12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☐ Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared orissued its audit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in thefiling reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ As of June30, 2025, the aggregate market value of voting stock held by non-affiliates of the Registrant, based on the closing price of the common stockon June30, 2025 (the last business day of the Registrant’s most recently completed second quarter) as quoted on the NYSE American, was approximately$21.1 million. As of March 18, 2026, 36,632,775 shares of the Registrant’s common stock were outstanding. Document Incorporated by ReferencePortions of the registrant’s Definitive Proxy Statement relating to the 2026 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120days after the end of the registrant’s fiscalyear ended December31, 2025, are incorporated by reference into PartIII of thisAnnual Report on Form 10-K. TABLE OF CONTENTS ARMATA PHARMACEUTICALS, INC. PageNo.PARTIItem1.Business6Item1A. Risk Factors48Item1B. Unresolved Staff Comments70Item 1C.Cybersecurity70Item2.Properties71Item3.Legal Proceedings72Item4.Mine Safety Disclosures72PARTIIItem5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of EquitySecurities72Item6.Reserved73Item7.Management’s Discussion and Analysis of Financial Condition and Results of Operations73Item7A.Quantitative and Qualitative Disclosures About Market Risk87Item8.Financial Statements and Supplementary Data87Item9.Changes In and Disagreements With Accountants on Accounting and Financial Disclosure116Item9A. Controls and Procedures116Item9B. Other Information117Item9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections117PARTIIIItem10.Directors, Executive Officers and Corporate Governance118Item11.Executive Compensation118Item12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters118Item13.Certain Relationships and Related Transactions and Director Independence118Item14.Principal Accountant Fees and Services118PARTIVItem15.Exhibits and Financial Statement Schedules119Item16.Form10-K Summary125Signaturesand Power of Attorney126 SPECIAL NOTEREGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (this “Annual Report”) and certain information incorporated herein byreference contain forward-looking statements, which are provided under the “safe harbor” protection of thePrivate Securities Litigation Reform Act of 1995. These statements relate to future events, results